Scholars@Duke
Dani Paul Bolognesi

Dani Paul Bolognesi

James B. Duke Distinguished Professor Emeritus of Medicine
Surgery, Surgical Sciences
dani.bolognesi@duke.edu
Box 3704 Med Ctr, Durham, NC 27710
204 Surg Oncol Res Fac, Durham, NC 27710
Manage Profile
Embed Profile Data

Selected Publications

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal Article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Conference Journal of Clinical Oncology · May 20, 2019 2060 Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ... Full text Link to item Cite

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Journal Article N Engl J Med · July 12, 2018 BACKGROUND: The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating ... Full text Link to item Cite

Heterobiaryl human immunodeficiency virus entry inhibitors.

Journal Article J Med Chem · July 23, 2009 Previously disclosed HIV (human immunodeficiency virus) attachment inhibitors, exemplified by BMS 806 (formally BMS378806, 1), are characterized by a substituted indole or azaindole ring linked to a benzoylpiperazine via a ketoamide or sulfonamide group. I ... Full text Link to item Cite

Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.

Journal Article J Med Chem · December 27, 2007 The crystal structures of many tertiary alpha-ketoamides reveal an orthogonal arrangement of the two carbonyl groups. Based on the hypothesis that the alpha-ketoamide HIV attachment inhibitor BMS 806 (formally BMS378806, 26) might bind to its gp120 target ... Full text Link to item Cite

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Journal Article Nat Rev Drug Discov · March 2004 Highly active antiretroviral therapy (HAART) based on combinations of drugs that target key enzymes in the life-cycle of human immunodeficiency virus (HIV) has considerably reduced morbidity and mortality from HIV infection since its introduction in the mi ... Full text Link to item Cite

Basic science in a department of surgery.

Journal Article Ann Surg · December 2003 Full text Link to item Cite

Introduction

Chapter · 2002 Cite

HIV fusion and its inhibition.

Journal Article Antiviral Res · May 2001 Full text Link to item Cite

Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.

Journal Article AIDS Res Hum Retroviruses · December 10, 2000 The heptad repeat regions HR1 and HR2 of HIV-1 gp41 can associate to form heterooligomers through helical coil-coil interactions that are believed to play a key role in virus-induced membrane fusion. The HR1/HR2 complex was proposed to be the core structur ... Full text Link to item Cite

Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.

Other AIDS · July 7, 2000 OBJECTIVES: To study memory T cell proliferative responses and cytokine profiles induced in HIV-1 seronegative volunteers immunized with a live recombinant canarypox vector expressing HIV-1 antigens (ALVAC-HIV) and boosted with a recombinant gp120 subunit ... Full text Link to item Cite

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.

Journal Article AIDS Res Hum Retroviruses · June 10, 2000 Several immunogens induce HIV-specific neutralization and in vitro lymphoproliferation in adults at low HIV-1 risk, but responses in persons at high HIV-1 risk are not known. We performed a multicenter, double-blinded, adjuvant-controlled trial with two gp ... Full text Link to item Cite

Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection.

Journal Article AIDS Res Hum Retroviruses · March 20, 2000 The purpose of this study was to determine whether thymic transplantation in addition to highly active antiretroviral therapy (HAART) will restore T cell function in HIV infection. Eight treatment-naive HIV-infected patients with CD4+ T cell counts of 200- ... Full text Link to item Cite

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.

Journal Article AIDS Res Hum Retroviruses · July 1, 1999 The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines to bind to oligomeric native HIV-1 envelope glycoproteins of primary isolates of HIV-1 was measured by flow cytometric indirect i ... Full text Link to item Cite

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.

Journal Article AIDS Res Hum Retroviruses · May 1, 1999 A live recombinant canarypox vector expressing HIV-1 gpl20 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 MN synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection for their safety and immunogen ... Full text Link to item Cite

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Other AIDS Res Hum Retroviruses · January 20, 1999 We evaluated prime-boost immunization with two recombinant envelope glycoprotein subunit vaccines (HIV-1MN recombinant gp160 vaccine in alum adjuvant [MN rgp160] and HIV-1MN recombinant gp120 vaccine in alum adjuvant [MN rgp120]) for safety and immunogenic ... Full text Link to item Cite

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Journal Article Nat Med · November 1998 T-20, a synthetic peptide corresponding to a region of the transmembrane subunit of the HIV-1 envelope protein, blocks cell fusion and viral entry at concentrations of less than 2 ng/ml in vitro. We administered intravenous T-20 (monotherapy) for 14 days t ... Full text Link to item Cite

Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.

Journal Article J Surg Res · October 1998 Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3-day ex vivo incubation in the pres ... Full text Link to item Cite

Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.

Journal Article J Virol · August 1998 Infection with attenuated simian immunodeficiency virus (SIV) in rhesus macaques has been shown to raise antibodies capable of neutralizing an animal challenge stock of primary SIVmac251 in CEMx174 cells that correlate with resistance to infection after ex ... Full text Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal Article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Conference Journal of Clinical Oncology · May 20, 2019 2060 Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ... Full text Link to item Cite

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Journal Article N Engl J Med · July 12, 2018 BACKGROUND: The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating ... Full text Link to item Cite

Heterobiaryl human immunodeficiency virus entry inhibitors.

Journal Article J Med Chem · July 23, 2009 Previously disclosed HIV (human immunodeficiency virus) attachment inhibitors, exemplified by BMS 806 (formally BMS378806, 1), are characterized by a substituted indole or azaindole ring linked to a benzoylpiperazine via a ketoamide or sulfonamide group. I ... Full text Link to item Cite

Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.

Journal Article J Med Chem · December 27, 2007 The crystal structures of many tertiary alpha-ketoamides reveal an orthogonal arrangement of the two carbonyl groups. Based on the hypothesis that the alpha-ketoamide HIV attachment inhibitor BMS 806 (formally BMS378806, 26) might bind to its gp120 target ... Full text Link to item Cite

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Journal Article Nat Rev Drug Discov · March 2004 Highly active antiretroviral therapy (HAART) based on combinations of drugs that target key enzymes in the life-cycle of human immunodeficiency virus (HIV) has considerably reduced morbidity and mortality from HIV infection since its introduction in the mi ... Full text Link to item Cite

Basic science in a department of surgery.

Journal Article Ann Surg · December 2003 Full text Link to item Cite

Introduction

Chapter · 2002 Cite

HIV fusion and its inhibition.

Journal Article Antiviral Res · May 2001 Full text Link to item Cite

Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.

Journal Article AIDS Res Hum Retroviruses · December 10, 2000 The heptad repeat regions HR1 and HR2 of HIV-1 gp41 can associate to form heterooligomers through helical coil-coil interactions that are believed to play a key role in virus-induced membrane fusion. The HR1/HR2 complex was proposed to be the core structur ... Full text Link to item Cite

Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.

Other AIDS · July 7, 2000 OBJECTIVES: To study memory T cell proliferative responses and cytokine profiles induced in HIV-1 seronegative volunteers immunized with a live recombinant canarypox vector expressing HIV-1 antigens (ALVAC-HIV) and boosted with a recombinant gp120 subunit ... Full text Link to item Cite

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.

Journal Article AIDS Res Hum Retroviruses · June 10, 2000 Several immunogens induce HIV-specific neutralization and in vitro lymphoproliferation in adults at low HIV-1 risk, but responses in persons at high HIV-1 risk are not known. We performed a multicenter, double-blinded, adjuvant-controlled trial with two gp ... Full text Link to item Cite

Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection.

Journal Article AIDS Res Hum Retroviruses · March 20, 2000 The purpose of this study was to determine whether thymic transplantation in addition to highly active antiretroviral therapy (HAART) will restore T cell function in HIV infection. Eight treatment-naive HIV-infected patients with CD4+ T cell counts of 200- ... Full text Link to item Cite

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.

Journal Article AIDS Res Hum Retroviruses · July 1, 1999 The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines to bind to oligomeric native HIV-1 envelope glycoproteins of primary isolates of HIV-1 was measured by flow cytometric indirect i ... Full text Link to item Cite

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.

Journal Article AIDS Res Hum Retroviruses · May 1, 1999 A live recombinant canarypox vector expressing HIV-1 gpl20 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 MN synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection for their safety and immunogen ... Full text Link to item Cite

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Other AIDS Res Hum Retroviruses · January 20, 1999 We evaluated prime-boost immunization with two recombinant envelope glycoprotein subunit vaccines (HIV-1MN recombinant gp160 vaccine in alum adjuvant [MN rgp160] and HIV-1MN recombinant gp120 vaccine in alum adjuvant [MN rgp120]) for safety and immunogenic ... Full text Link to item Cite

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Journal Article Nat Med · November 1998 T-20, a synthetic peptide corresponding to a region of the transmembrane subunit of the HIV-1 envelope protein, blocks cell fusion and viral entry at concentrations of less than 2 ng/ml in vitro. We administered intravenous T-20 (monotherapy) for 14 days t ... Full text Link to item Cite

Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.

Journal Article J Surg Res · October 1998 Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3-day ex vivo incubation in the pres ... Full text Link to item Cite

Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.

Journal Article J Virol · August 1998 Infection with attenuated simian immunodeficiency virus (SIV) in rhesus macaques has been shown to raise antibodies capable of neutralizing an animal challenge stock of primary SIVmac251 in CEMx174 cells that correlate with resistance to infection after ex ... Full text Link to item Cite

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

Journal Article J Virol · April 1998 The magnitude and breadth of neutralizing antibodies raised in response to infection with chimeric simian-human immunodeficiency virus (SHIV) in rhesus macaques were evaluated. Infection with either SHIV-HXB2, SHIV-89.6, or SHIV-89.6PD raised high-titer ne ... Full text Link to item Cite

Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.

Journal Article J Virol · March 1998 Human immunodeficiency virus type 1 (HIV-1) uses a variety of chemokine receptors as coreceptors for virus entry, and the ability of the virus to be neutralized by antibody may depend on which coreceptors are used. In particular, laboratory-adapted variant ... Full text Link to item Cite

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Other Vaccine · March 1998 The safety and immunogenicity of HIV-1MN recombinant gp160 (MN rgp160) vaccine in healthy, uninfected volunteers was tested in a double-blind study with a factorial design. By random assignment, 20 volunteers received three 200 micrograms doses of MN rgp16 ... Full text Link to item Cite

HIV vaccines. Viral envelope fails to deliver?

Journal Article Nature · February 12, 1998 Full text Link to item Cite

New perspectives on AIDS vaccine development: Editorial

Journal Article AIDS Research and Human Retroviruses · January 1, 1998 Cite

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Journal Article J Infect Dis · October 1997 The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poorly understood and was assessed by evaluating responses at different stages of infection. Undiluted sera from long-term nonprogressors (LTNP) had broad neutr ... Full text Link to item Cite

HIV. A clever hijacker of the immune system.

Journal Article Curr Opin Immunol · August 1997 Full text Link to item Cite

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Journal Article Proc Natl Acad Sci U S A · February 18, 1997 A fundamental goal of current strategies to develop an efficacious vaccine for AIDS is the elicitation of broadly reactive cytotoxic T lymphocyte (CTL) reactivities capable of destroying virally infected targets. Recent application of recombinant canarypox ... Full text Link to item Cite

Editorial.

Journal Article Pulm Pharmacol Ther · February 1997 No abstract Copyright 1997 Academic Press Limited ... Full text Link to item Cite

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

Journal Article Ann Intern Med · August 15, 1996 OBJECTIVE: To evaluate the safety and immunogenicity of recombinant glycoprotein (rgp) 120, a candidate vaccine for the human immunodeficiency virus (HIV), formulated with a novel adjuvant, MF59, with or without a biological response modifier, MTP-PE. DESI ... Full text Link to item Cite

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

Journal Article Clin Diagn Lab Immunol · July 1996 The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines the bind to oligomeric native and monomeric recombinant HIV-1 envelope glycoproteins (rgp 120) was measured in 25 uninfected, hea ... Full text Link to item Cite

Overview of HIV vaccine development.

Journal Article Antibiot Chemother (1971) · 1996 Full text Link to item Cite

Measurements of humoral immune responses directed to HIV-1: Comparison of infection and vaccine induced antibody reactivities

Journal Article Medecine Biologie Environnement · December 1, 1995 Neutralizing antibody repsonses to natural infection of humans and experimental infection of chimpanzees are compared to those induced by candidate HIV-1 vaccines and to several monoclonal antibodies. The studies were directed to the apparent neutralizatio ... Cite

Immunodeficiency.

Journal Article Curr Opin Immunol · August 1995 Full text Link to item Cite

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Journal Article Clin Exp Immunol · August 1995 CD8+ cytotoxic T lymphocytes are an important component in the immunologic control of human viral diseases. IL-7, a stromal cell-derived cytokine, has been demonstrated to enhance both anti-tumour and anti-viral CTL as well as lymphokine-activated killer ( ... Full text Link to item Cite

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.

Journal Article J Virol · June 1995 We have previously reported that synthetic peptides representing the leucine zipper domain (DP107) and a second putative helical domain (DP178) of human immunodeficiency virus type 1 (HIV-1) gp41 exhibit potent anti-HIV activity. In this study we have used ... Full text Link to item Cite

Multiple CTL specificities against autologous HIV-1-infected BLCLs.

Journal Article Cell Immunol · March 1995 The cellular immune response to HIV-1 has been well studied but, in many respects, remains incompletely defined. Although CTL specificities against highly conserved HIV-1 determinants as dictated by vaccinia/HIV-1 vector constructs have been described, muc ... Full text Link to item Cite

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

Journal Article AIDS Res Hum Retroviruses · December 1994 We examined the safety and immunogenicity of a baculovirus-derived recombinant HIV-1 envelope glycoprotein vaccine candidate, rgp160 (VaxSyn; MicroGeneSys, Meriden, CT), administered at doses of 160 or 640 micrograms to 56 healthy, HIV-1-seronegative adult ... Full text Link to item Cite

NIH conference. HIV vaccine development: a progress report.

Journal Article Ann Intern Med · October 15, 1994 The development of a safe, effective preventive vaccine for human immunodeficiency virus (HIV) infection remains an area of vigorous research. Several highly innovative vaccine candidates are being developed, and more than 13 vaccine candidates have been t ... Full text Link to item Cite

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.

Journal Article J Infect Dis · October 1994 Priming with a live recombinant vector followed by subunit boosting is a promising strategy for human immunodeficiency virus (HIV) immunization. Twenty-nine vaccinia-naive volunteers were primed with gp160-recombinant vaccinia virus (HIVAC-1e) and boosted ... Full text Link to item Cite

HIV infection in vaccinated volunteers.

Journal Article JAMA · August 10, 1994 Full text Link to item Cite

HIV Infection in Vaccinated Volunteers

Journal Article JAMA: The Journal of the American Medical Association · August 10, 1994 Full text Cite

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Journal Article JAMA · August 10, 1994 OBJECTIVE: To evaluate the safety and immunogenicity of the MN strain of recombinant gp120 (MN rgp120) as a vaccine prototype to prevent human immunodeficiency virus (HIV). DESIGN: Double-blind, randomized, placebo-controlled study with subjects vaccinated ... Full text Link to item Cite

Immunodeficiency.

Journal Article Curr Opin Immunol · August 1994 Full text Link to item Cite

The viral transmembrane protein: A target for the discovery of novel antivirals

Journal Article International Antiviral News · July 22, 1994 Cite

Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees.

Journal Article J Acquir Immune Defic Syndr (1988) · April 1994 Despite its shortcomings as a disease model, the chimpanzee is still the most relevant animal model for human immunodeficiency virus type 1 (HIV-1) infection. Previous studies have revealed qualitative differences between human and chimpanzee anti-HIV-1 re ... Link to item Cite

Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Journal Article J Virol · April 1994 It has been shown previously that the major neutralizing epitopes in simian immunodeficiency virus (SIV) are discontinuous and conformation dependent and that the V3 loop, in contrast to that of human immunodeficiency virus (HIV) type 1, does not by itself ... Full text Link to item Cite

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

Journal Article J Infect Dis · December 1993 Recombinant gp160 derived from human immunodeficiency virus type 1 (HIV-1)IIIB and produced in mammalian tissue culture cells using a vaccinia virus expression system (rgp160-mam) was evaluated as a vaccine in combination with alum and deoxycholate adjuvan ... Full text Link to item Cite

CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism.

Journal Article AIDS Res Hum Retroviruses · November 1993 HIV-1 infection evokes a vigorous antiviral response that may participate in resolving the initial peak of plasma viremia and maintenance of the asymptomatic state. CD8+ T lymphocytes of HIV-1-infected individuals play a critical role in the cellular anti- ... Full text Link to item Cite

Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

Journal Article J Immunol · August 1, 1993 We have tested synthetic peptides composed of Th (T1) and V3 loop B cell neutralizing determinants [SP10 MN(A)] of HIVMN gp120 and the fusogenic (F) domain of gp41 as immunogens in rhesus monkeys. After two immunizations with either HIV env peptide T1-SP10 ... Link to item Cite

The immune response to HIV: implications for vaccine development.

Journal Article Semin Immunol · June 1993 HIV infection is accompanied by a vigorous immune response to the virus consisting of humoral and cellular elements that effectively neutralize virus infectivity and lyse infected cells when analyzed in cell culture models. However, this immune response sh ... Full text Link to item Cite

AIDS. Where has HIV been hiding?

Journal Article Nature · March 25, 1993 Full text Link to item Cite

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Journal Article J Infect Dis · March 1993 Twelve vaccinia-naive volunteers were inoculated with recombinant vaccinia virus expressing the human immunodeficiency virus type 1 (HIV-1) strain IIIB (HIV-1IIIB) envelope glycoprotein gp160 and subsequently immunized with 640 micrograms of recombinant (r ... Full text Link to item Cite

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.

Journal Article J Exp Med · March 1, 1993 The fusogenic (F) domain of human immunodeficiency virus (HIV) gp41 envelope (env) protein has sequence similarities to many virus and mediates the fusion of HIV-infected cells. During a survey of the immunogenicity of HIV env peptides in chimpanzees, we h ... Full text Link to item Cite

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Journal Article Proc Natl Acad Sci U S A · November 1, 1992 A peptide designated DP-107 was synthesized containing amino acid residues 558-595 of the envelope glycoprotein gp160 of human immunodeficiency virus type 1 strain LAI (HIV-1LAI). Algorithms for secondary structure have predicted that this region of the en ... Full text Link to item Cite

Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.

Journal Article J Clin Microbiol · October 1992 The ability of antibody induced by vaccination with recombinant gp160 (rgp160) to bind to native and recombinant human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins was measured. Thirty-three HIV-1-seronegative healthy adult volunteers were ... Full text Link to item Cite

Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus.

Journal Article AIDS Res Hum Retroviruses · September 1992 More than 200 sera from macaques immunized with several different vaccine preparations were tested in various assays with cells of human and macaque origin. Only in instances where whole inactivated SIV preparations were used for immunization, were reactiv ... Full text Link to item Cite

Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells.

Journal Article Biochem Biophys Res Commun · August 31, 1992 The mass levels of bioactive lipids known to modulate signal transduction or to possess other biological activities were measured in HIV-infected CEM cells. The levels of diacylglycerol, an activator of protein kinase C, as well as of alkylacylglycerol wer ... Full text Link to item Cite

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells.

Journal Article Antimicrob Agents Chemother · May 1992 Synthetic peptide analog inhibitors of human immunodeficiency virus type 1 (HIV-1) protease were used to study the effects of inhibition of polyprotein processing on the assembly, structure, and infectivity of virions released from a T-cell line chronicall ... Full text Link to item Cite

The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.

Journal Article Proc Natl Acad Sci U S A · February 15, 1992 To identify the principal neutralization determinant (PND) of simian immunodeficiency virus (SIV), antisera were generated using recombinant gp110 [the SIV analog of the human immunodeficiency virus type 1 (HIV-1) external envelope glycoprotein, gp120], gp ... Full text Link to item Cite

Development of a vaccine for the prevention of AIDS, a critical appraisal.

Journal Article Vaccine · 1992 The pathogenesis and clinical expression of HIV-1 infection in humans is considered in terms of classical pathogenetic studies of viral infections for which successful vaccines have been produced. The unique features of HIV pathogenesis are defined, and ga ... Full text Link to item Cite

Perspectives on the development of anti-HIV vaccines.

Journal Article Curr Opin Biotechnol · December 1991 Progress towards the development of a vaccine against acquired immune deficiency syndrome is proceeding along several fronts. First and foremost, it rests on the basic research being done with the virus, particularly its mechanisms of replication, pathogen ... Full text Link to item Cite

Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages.

Journal Article J Virol · August 1991 The influence of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of freshly isolated normal human peritoneal macrophages and blood monocytes was examined. Each of 14 HIV antibody-positive human serum samples was found to ... Full text Link to item Cite

The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals.

Journal Article Cell Immunol · August 1991 Human immunodeficiency virus type-1 (HIV-1)-infected individuals exhibit functional impairment in various forms of cell-mediated cytotoxicities (CMC) at all stages of disease. The purpose of this study was to determine (i) if peripheral blood mononuclear c ... Full text Link to item Cite

In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251.

Journal Article AIDS Res Hum Retroviruses · August 1991 Sensitive and reproducible assays for SIV infection and syncytium formation have been developed in which high titers of neutralizing and fusion-inhibiting antibodies can be recorded. These assays will contribute toward our understanding of the role of humo ... Full text Link to item Cite

AIDS vaccines: progress and unmet challenges.

Journal Article Ann Intern Med · January 15, 1991 Full text Link to item Cite

HIV vaccine development: perspective.

Journal Article Biotechnol Ther · 1991 Link to item Cite

SIV vaccine protection of rhesus monkeys.

Journal Article Biotechnol Ther · 1991 Rhesus macaques (M. mulatta), immunized with an inactivated whole SIVmac vaccine and muramyl dipeptide or Freund's incomplete adjuvant, were protected against IV challenge infection with 10 animal infectious doses of the homologous virus. The protection in ... Link to item Cite

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Journal Article Science · December 14, 1990 The principal neutralizing determinant (PND) of human immunodeficiency virus (HIV)-1 resides within the V3 loop of the envelope protein. Antibodies elicited by peptides of this region were able to neutralize diverse isolates. Serum from one of three animal ... Full text Link to item Cite

HIV: Vaccine and treatment strategies

Conference Archives of AIDS Research · December 1, 1990 Cite

Vaccines and immunology: Overview

Journal Article AIDS · December 1, 1990 Cite

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

Journal Article J Immunol · November 15, 1990 In an effort to determine the functional activity of anti-HIV-1 human mAb and to define the epitopes against which they are directed, supernatants from 10 EBV-transformed lymphoblastoid cell lines producing mAb to HIV were tested. Five clones producing mAb ... Link to item Cite

Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

Journal Article J Immunol · October 15, 1990 We have previously described a synthetic peptide (T1-SP10) derived from two noncontiguous regions of HTLVIIIB envelope gp120 (T1, amino acids 428-443; SP10, amino acids 303-321) that induced type-specific anti-HIV neutralizing antibodies and T cell prolife ... Link to item Cite

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Journal Article Science · August 24, 1990 The principal neutralizing determinant (PND) of human immunodeficiency virus HIV-1 is part of a disulfide bridged loop in the third variable region of the external envelope protein, gp120. Analysis of the amino acid sequences of this domain from 245 differ ... Full text Link to item Cite

Vaccine development for HIV infection.

Journal Article J Am Acad Dermatol · June 1990 The immune response that develops subsequent to infection with human immunodeficiency virus (HIV) consists of both humoral and cellular elements that, when tested in vitro, can inhibit virus infection and syncytium formation and lyse virus-infected target ... Full text Link to item Cite

Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.

Journal Article J Immunol · May 1, 1990 HIV-1-specific cell-mediated cytotoxicity (CMC) is a form of antibody-dependent cellular cytotoxicity (ADCC) in which HIV-1-specific antibodies arm NK cells directly to become cytotoxic for targets bearing HIV-1 antigenic determinants. This non-MHC-restric ... Link to item Cite

Immunobiology of the human immunodeficiency virus envelope and its relationship to vaccine strategies.

Journal Article Mol Biol Med · February 1990 The envelope of human immunodeficiency virus (HIV) is an essential building block of the virus and it plays a major role in its life-cycle, particularly during the early stages of infection. It very likely determines, at least in part, the host range and t ... Link to item Cite

Approaches to HIV vaccine design.

Journal Article Trends Biotechnol · February 1990 Contemporary vaccines are relying increasingly on modern biotechnology and a vaccine against the AIDS virus is expected to depend even more on new technological advances. Four basic areas of vaccine development are discussed in this context: (1) selection ... Full text Link to item Cite

Progress in vaccine development against SIV and HIV.

Journal Article J Acquir Immune Defic Syndr (1988) · 1990 Link to item Cite

Introduction

Journal Article AIDS Research and Human Retroviruses · January 1, 1990 Full text Cite

Editorial

Journal Article AIDS Research and Human Retroviruses · January 1, 1990 Full text Cite

Progress in vaccines against AIDS.

Journal Article Science · December 8, 1989 Full text Link to item Cite

The antiretroviral effects of lymphokine-activated killer cells

Conference Surgical Forum · December 1, 1989 Cite

Cytokine augmentation of human immunodeficiency virus type 1 (HIV-1) gp120-specific cellular cytotoxicity.

Journal Article J Biol Response Mod · October 1989 Currently available anti-human immunodeficiency virus type 1 (HIV-1) agents such as azidothymidine can prevent de novo virus infection in vitro but lack significant activity against chronically infected cells. Our laboratory has recently described glycopro ... Link to item Cite

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Journal Article Proc Natl Acad Sci U S A · September 1989 The principal neutralizing determinant of human immunodeficiency virus type 1 (HIV-1) is located in the external envelope protein, gp120, and has previously been mapped to a 24-amino acid-long sequence (denoted RP135). We show here that deletion of this se ... Full text Link to item Cite

Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

Journal Article J Immunol · May 15, 1989 In previous studies, we have used antisera raised to envelope (env)-gene-encoded synthetic peptides to identify a region of (HIV) glycoprotein (gp) 120 env protein designated SP10 that contains a type-specific neutralizing determinant. To develop a polyval ... Link to item Cite

HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.

Journal Article J Immunol · May 1, 1989 The magnitude of immunologic defects observed in HIV-1-infected individuals before the development of overt AIDS is disproportionately high in comparison to the levels of infectious virus in these patients--suggesting that factors other than direct virus-i ... Link to item Cite

GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.

Journal Article J Immunol · February 15, 1989 Fresh circulating PBMC from HIV-1 seropositive individuals have been found to mediate specific, non-MHC restricted lysis of targets expressing the major envelope glycoprotein of HIV-1, gp120, in 6-h 51Cr release assays. This gp120 specific cell-mediated cy ... Link to item Cite

Immunobiology of the HIV envelope.

Journal Article Ann N Y Acad Sci · 1989 Full text Link to item Cite

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Journal Article J Virol · November 1988 Animals immunized with the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally due to antibodies directed toward a hypervariable region o ... Full text Link to item Cite

AIDS vaccines.

Journal Article Sci Am · October 1988 Full text Link to item Cite

The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus.

Journal Article Virology · October 1988 Passive anti-viral immunotherapy greatly suppresses the incidence of spontaneous leukemia in AKR mice, rendering the thymus of successfully treated animals devoid of infectious ecotropic retrovirus. Reconstitution assays have determined that the thymic and ... Full text Link to item Cite

Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain.

Journal Article Proc Natl Acad Sci U S A · August 1988 The external segment of the T4 (CD4) glycoprotein functions as the T-cell surface receptor for human immunodeficiency virus by binding the major viral coat protein (gp120) with relatively high affinity. To more precisely define the region of T4 involved in ... Full text Link to item Cite

Natural immunity to HIV and its possible relationship to vaccine strategies.

Journal Article Microbiol Sci · August 1988 This discussion examines various potential targets of immune attack on human immunodeficiency virus (HIV) as recognized by antibodies obtained experimentally as well as under natural conditions of infection. Various issues related to vaccine strategies are ... Link to item Cite

Cellular immune response to viral peptides in patients exposed to HIV.

Journal Article AIDS Res Hum Retroviruses · August 1988 In efforts to identify B cell and T cell epitopes of HIV-1 structural components, serum as well as lymphocytes from HIV-1-seropositive individuals were reacted with several recombinant and native peptides representing defined viral gag and env determinants ... Full text Link to item Cite

Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines.

Journal Article J Exp Med · August 1, 1988 Derivatives of the CEM T and WIL-2 B cell lines showed striking diversity in their responses to the HTLV-IIIB strain of the human immunodeficiency virus (HIV). Several stable phenotypic patterns could be defined, based on whether cells were permissive (P+, ... Full text Link to item Cite

Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Journal Article Proc Natl Acad Sci U S A · May 1988 Antisera to recombinant human immunodeficiency virus (HIV) proteins containing the entire envelope, gp160, or the central portion of the envelope, PB1, can inhibit fusion of virally infected cells in culture. This fusion inhibition is HIV-variant specific- ... Full text Link to item Cite

Transmission of human immunodeficiency virus to sexual partners of hemophiliacs.

Journal Article Am J Hematol · May 1988 To examine the variables associated with heterosexual transmission of human immunodeficiency virus (HIV), we studied 32 couples in our hemophilia center who had steady sexual relationships for periods more than 1 year. Of the 32 sexual partners of the hemo ... Full text Link to item Cite

Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals.

Journal Article Lancet · April 23, 1988 Forty-one patients seropositive for human immunodeficiency virus type 1 (HIV-1) were assessed for cell-mediated cytotoxicity (CMC) against autologous target cells bearing the major envelope glycoprotein of HIV-1, gp120. Effector lymphocytes from over 85% o ... Full text Link to item Cite

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Journal Article Proc Natl Acad Sci U S A · March 1988 A synthetic peptide (SP-10-IIIB) with an amino acid sequence [Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Arg-Ile-Gln-Arg-Gly-Pro -Pro-Gly-(Tyr); amino acids 303-321] from the human immunodeficiency virus (HIV) isolate human T-cell lymphotropic virus t ... Full text Link to item Cite

Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay.

Journal Article AIDS Res Hum Retroviruses · February 1988 A rapid, simple, reproducible and semi-quantitative assay to measure neutralizing antibodies has been developed. It employs a unique cell line which is exquisitively sensitive to infection with all HIV isolates tested. The assay is amenable to microtiter f ... Full text Link to item Cite

The coenrichment of stem cells, prothymocytes, and stromal elements with ecotropic retrovirus-producing cells from the bone marrow of leukemia-prone AKR mice.

Journal Article Virology · February 1988 Ecotropic virus-producing cells in the bone marrow of the leukemia-prone AKR strain of mice were significantly enriched by fractionation on discontinuous density gradients of Percoll and were found in a low-density population of cells comprised predominant ... Full text Link to item Cite

AZT inhibits HIV-1 replication in monocytes.

Journal Article J Acquir Immune Defic Syndr (1988) · 1988 Link to item Cite

Loss of tumorigenicity following in vitro MuLV infection is associated with induction of peritoneal natural killer cell activity.

Journal Article Adv Exp Med Biol · 1988 Infection by an attenuated replication-competent murine retrovirus (Friend leukemia virus-FLV4), but not other non-transforming retroviruses, stimulated rejection of transplantable thymomas (RL-cell line) and subsequent tumor immunity in syngeneic mouse re ... Full text Link to item Cite

The effects of leukemosuppressive immunotherapy on thymic infectious cell centers in AKR mice.

Journal Article Thymus · 1988 Although cortical thymocytes were found to be the predominant ecotropic and MCF-virus producers in the thymus of leukemia prone AKR mice the initial ecotropic retrovirus producing cells have been detected among a low density subpopulation of thymocytes inc ... Link to item Cite

Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.

Journal Article Proc Natl Acad Sci U S A · December 1987 The major envelope glycoprotein of a human immunodeficiency virus (HIV) has been purified and was utilized as a prototype vaccine in chimpanzees. The 120,000-dalton glycoprotein (gp120) was purified from membranes of human T-lymphotropic virus (HTLV)-IIIB- ... Full text Link to item Cite

Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.

Journal Article Proc Natl Acad Sci U S A · October 1987 The human immunodeficiency virus envelope gene was expressed in insect cells by using a Baculovirus expression vector. The protein has an apparent molecular mass of 160 kDa, appears on the surface of infected insect cells, and does not appear to be cleaved ... Full text Link to item Cite

Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome.

Journal Article Proc Natl Acad Sci U S A · August 1987 Previous studies have demonstrated that the onset of AKR leukemia could be dramatically delayed and the overall incidence significantly reduced following treatment with high-titered heterologous antibodies directed against the gp71 major glycoprotein of th ... Full text Link to item Cite

Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

Journal Article Proc Natl Acad Sci U S A · August 1987 Interactions between retroviruses associated with acquired immunodeficiency syndrome and their receptors on lymphocytes represent the initial steps in the process of infection and are also involved in multinucleated giant cell formation, which is one form ... Full text Link to item Cite

Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

Journal Article Proc Natl Acad Sci U S A · July 1987 The lymphocyte differentiation antigen CD4 serves as a receptor for human retroviruses associated with acquired immunodeficiency syndrome (AIDS) through its interaction with the major envelope virion glycoprotein, gp120, which is also expressed on the surf ... Full text Link to item Cite

Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.

Journal Article J Virol · June 1987 The human immunodeficiency virus (HIV)-specific lymphocyte proliferation response was determined for 40 persons at different stages of HIV infection. The specific response to purified HIV virion antigens from strain HTLV-IIIB was poor, occurred in only 9 o ... Full text Link to item Cite

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.

Journal Article Proc Natl Acad Sci U S A · April 1987 A highly immunogenic epitope from a conserved COOH-terminal region of the human immunodeficiency virus (HIV) gp120 envelope protein has been identified with antisera from HIV-seropositive subjects and a synthetic peptide (SP-22) containing 15 amino acids f ... Full text Link to item Cite

The effects of leukemosuppressive immunotherapy on bone marrow infectious cell centers in AKR mice.

Journal Article Virology · April 1987 The bone marrow of AKR mice is the richest source of infectious ecotropic cell centers (ICCs) during the neonatal period. The bone marrow ICCs reside in a low-density population expressing high levels of viral glycoprotein (gp71) and Class I histocompatibi ... Full text Link to item Cite

Prospects for development of a vaccine against HIV-related disorders

Other Clinical Immunology Newsletter · January 1, 1987 Full text Cite

Augmentation of anti-HIV ADCC with interleukin-2

Journal Article Surgical Forum · January 1, 1987 Cite

Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.

Journal Article Haematol Blood Transfus · 1987 By analogy to other retroviruses, the major envelope glycoprotein - gp120 - of HTLV-III/LAV is a probable target for neutralizing antibody. This antigen has been purified from H9 cells chronically infected with the HTLV-IIIB prototype strain. Several goats ... Full text Link to item Cite

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Journal Article Science · December 12, 1986 Immunization with either an Escherichia coli recombinant segment of the human T-cell lymphotropic virus (HTLV-III/LAV) envelope protein (gp 120) or with deglycosylated gp 120 envelope protein produced antibodies that neutralize HTLV-III/LAV infection in vi ... Full text Link to item Cite

Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Journal Article Proc Natl Acad Sci U S A · December 1986 By analogy to other retroviruses, the major envelope glycoprotein, gp120, of human T-lymphotropic virus type III (HTLV-III) is a probable target for neutralizing antibody. This antigen has been purified from H9 cells chronically infected with the HTLV-IIIB ... Full text Link to item Cite

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Journal Article Proc Natl Acad Sci U S A · November 1986 The thymidine analog 3'-azido-3'-deoxythymidine (BW A509U, azidothymidine) can inhibit human immunodeficiency virus (HIV) replication effectively in the 50-500 nM range [Mitsuya, H., Weinhold, K. J., Furman, P. A., St. Clair, M. H., Nusinoff-Lehrman, S., G ... Full text Link to item Cite

Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.

Journal Article Proc Natl Acad Sci U S A · September 1986 This study initiates an effort to develop a safe vaccine against the acquired immunodeficiency syndrome (AIDS) that is caused by infection with a retrovirus designated human immunodeficiency virus (HIV) [formerly human T-cell lymphotropic virus type III (H ... Full text Link to item Cite

Properties of mouse leukemia viruses: XX. Variation of AKR Substrains in response to antibody therapy.

Journal Article Virology · April 15, 1986 In previous reports in this series, we have demonstrated that treatment of young AKR mice with IgG prepared against the viral envelope glycoprotein suppresses the development of spontaneous leukemia. Moreover, animals exhibiting high anti-viral antibody ti ... Full text Link to item Cite

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Journal Article Lancet · March 15, 1986 In a 6-week clinical trial 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related ... Full text Link to item Cite

Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III)

Journal Article Cancer Research · December 1, 1985 The continuous increase in the number of acquired immunodeficiency syndrome (AIDS) cases for whom no effective therapy is currently possible mandates attempts at developing primary prevention by a vaccine. Two basic unknowns are considered important: the i ... Cite

Prospects for treatment of human retrovirus-associated diseases

Journal Article Cancer Research · December 1, 1985 Overwhelming evidence has been obtained over the past 2 years that human T-cell leukemia virus type III (HTLV-III) is the primary cause of acquired immunodeficiency syndrome. The direct cytopathic effect of the virus on T4 helper cells demonstrated in vitr ... Cite

Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A.

Journal Article J Natl Cancer Inst · October 1985 The mechanism by which IgG2A from a syngeneic antitumor hyperimmune serum mediates destruction of target cells in the presence of thioglycollate-elicited peritoneal macrophages was investigated by using an in vitro assay system. Labeled tumor cells were fo ... Link to item Cite

Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells.

Journal Article J Natl Cancer Inst · October 1985 Attempts were made to augment the antibody-dependent killing of the ascitic AD755a tumor in vivo to protect C57BL/6J mice against the outgrowth of larger tumor burdens. The lethal dose for this tumor is less than 100 cells, and antibodies contained in a hy ... Link to item Cite

Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.

Journal Article J Natl Cancer Inst · October 1985 The antibody-dependent lytic activity of Corynebacterium parvum-induced peritoneal exudate cells was examined in vitro by utilizing AD755a tumor targets and a homologous anti-AD755a hyperimmune serum. Maximum antibody-dependent cell-mediated cytolysis (ADC ... Link to item Cite

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Journal Article Proc Natl Acad Sci U S A · October 1985 The acquired immune deficiency syndrome (AIDS) is thought to result from infection of T cells by a pathogenic human retrovirus, human T-lymphotropic virus type III (HTLV-III) or lymphadenopathy-associated virus (LAV). In this report, we describe the antivi ... Full text Link to item Cite

Prospects for treatment of human retrovirus-associated diseases.

Journal Article Cancer Res · September 1985 Overwhelming evidence has been obtained over the past 2 years that human T-cell leukemia virus type III (HTLV-III) is the primary cause of acquired immunodeficiency syndrome. The direct cytopathic effect of the virus on T4 helper cells demonstrated in vitr ... Link to item Cite

Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).

Journal Article Cancer Res · September 1985 The continuous increase in the number of acquired immunodeficiency syndrome (AIDS) cases for whom no effective therapy is currently possible mandates attempts at developing primary prevention by a vaccine. Two basic unknowns are considered important: the i ... Link to item Cite

Murine in vitro antigenic modification of tumor cells: effect on susceptibility to natural cell-mediated cytotoxicity.

Journal Article J Natl Cancer Inst · March 1985 A 3-methylcholanthrene [(MCA) CAS: 56-49-5]-induced fibrosarcoma cell line and its Friend murine leukemia virus-infected counterpart were assessed for their susceptibility to lysis by so-called "natural" effector cells in a series of 51Cr release assays. D ... Link to item Cite

Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus.

Journal Article Virology · May 1984 Administration of high-titered goat anti-FLV gp71 IgG to AKR mice during a narrow neonatal therapy "window" suppresses the early development of MuLV infectious cell centers (ICC) in spleen, thymus, and bone marrow. By 4-5 weeks of age ICC appear in spleen ... Full text Link to item Cite

Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV.

Journal Article J Exp Med · April 1, 1984 Four monoclonal antibodies, human T cell leukemia-lymphoma virus (HTLV) 6, 7, 8, and 9, which react with the 24,000 dalton internal core protein of HTLVI, have been developed. These monoclonal antibodies reacted with only HTLV-infected cells and not with a ... Full text Link to item Cite

Antibody-dependent cytolysis (ADCC) of tumor cells by activated murine macrophages is a two-step process: quantification of target binding and subsequent target lysis.

Journal Article Cell Immunol · January 1984 To analyze the antibody-dependent cell-mediated cytotoxicity (ADCC) reaction between tumor cells and activated murine macrophages in detail, it must be first determined if physical binding occurred between the two cell types. Over 15-20 min in vitro, antib ... Full text Link to item Cite

[Stimulation of immunoreactivity against endogenous retroviruses and protection against leukemia in aged AKR mice after vaccination with antibodies to viral surface components. The role of antibodies to p15(E)].

Journal Article Z Naturforsch C Biosci · 1984 Antibody against viral gp71 is effective therapeutically for high leukemic AKR mice if injected immediately after birth. No corresponding effect could be observed after inoculation later in life when the endogenous virus burden is already high. However, if ... Link to item Cite

Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis.

Journal Article Proc Natl Acad Sci U S A · April 1983 We have identified a Japanese patient with adult T-cell leukemia (ATL) whose T cells in vitro produced the human T-cell leukemia virus (HTLV). This patient presented with lymphomatous arthritis and leukemia and subsequently developed skin lesions. Skin inv ... Full text Link to item Cite

Elevated serum secretory immunoglobulin A levels in patients with head and neck carcinoma.

Journal Article Otolaryngol Head Neck Surg · April 1983 Secretory immunoglobulin A (SIgA) is a major component of the secretory immune system and has been demonstrated in the sera of patients with various pathologic conditions. Current studies were undertaken to quantitate secretory components (SC) in sera of p ... Full text Link to item Cite

Secretory immune response in patients with oropharyngeal carcinoma.

Journal Article Ann Otol Rhinol Laryngol · 1983 The secretory immune system is a unique, local immunological mechanism which appears to be independent of systemic immunity. Secretory immunoglobulin A (SIgA), a major component in this mucosal immune system, is structurally different from the IgA immunogl ... Full text Link to item Cite

Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies.

Journal Article J Natl Cancer Inst · August 1982 Many murine tumor models associated with murine leukemia virus(es) (MuLV) have been successfully treated by passive administration of antiviral antibodies. There is a large body of virus-negative tumors, however, which are lowly antigenic and thus refracto ... Link to item Cite

Function of the secretory immune system in bronchogenic carcinoma. Immunoglobulin A levels in respiratory secretions.

Journal Article J Thorac Cardiovasc Surg · July 1981 This study was designed to investigate the association between bronchogenic carcinoma of the lung and elevated immunoglobulin A (IgA) levels in respiratory secretions. Sixty-nine patients underwent bronchoscopic examination for evaluation of benign and mal ... Link to item Cite

In vivo antigenic modification of tumor cells. III. Metastatic thymic lymphoma specifically infected by thymotropic retrovirus.

Journal Article J Natl Cancer Inst · July 1981 Tissue distribution of radiation leukemia virus (RadLV) was examined after its inoculation into normal C57BL/6J (B6) mice, B6 mice bearing a transplantable, non-virus-producing thymic lymphoma (RL12-NP), and B6 mice bearing a transplanted non-virus produci ... Link to item Cite

In vivo antigenic modification of tumor cells. II. Distribution of virus in sarcoma-bearing mice.

Journal Article J Natl Cancer Inst · July 1981 Murine leukemia viruses were previously demonstrated to be able to infect efficiently non-virus-expressing tumors in vivo. In the present study the infectivity and tissue distribution of Friend murine leukemia virus (F-MuLV) in normal and tumor-bearing C57 ... Link to item Cite

In vivo antigenic modification of tumor cells. I. Introduction of murine leukemia virus antigens on non-virus-producing murine sarcomas.

Journal Article J Natl Cancer Inst · July 1981 Murine oncovirus antigens represent excellent targets for immune recognition, and virus-associated tumors are generally susceptible to various immunotherapy protocols. Virus-negative tumors, however, are nonimmunogenic and refractory to immunologic control ... Link to item Cite

Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum.

Journal Article J Immunol · June 1981 The potent capacity of B6 anti-AD755a tumor cell serum to protect mice against challenge with large doses of the homologous tumor cells has been shown to reside in the IgG2a antibody subclass. Despite their inability to protect in vivo, other IgG subclass ... Link to item Cite

Immunologic control of the ascites form of murine adenocarcinoma 755. III. Efficacy of serum therapy is controlled by a single genetic locus.

Journal Article J Immunol · June 1981 We have previously described a passive serum therapy system in which potent protection against challenge of syngeneic mice with large doses (10(4) X LD100) of AD755a tumor cells can be accomplished by administration of as little as 2 to 5 microliters/mouse ... Link to item Cite

Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction.

Journal Article J Immunol · June 1981 An in vitro assay has been developed that mimics the potent in vivo protective capacity of B6 anti-AD755a serum in a passive therapy protocol. In the presence of small volumes of hyperimmune serum or IgG2a antibody, thioglycollate-elicited B6 mouse periton ... Link to item Cite

Characterization of antigens in SSV nonproducer cells.

Journal Article Haematol Blood Transfus · 1981 An autologous antiserum against simian sarcoma virus (SSV) nonproducer cells (SSV-NP cells) was characterized by radioimmunoprecipitation. It reacts specifically with two different molecules in SSV-NP cells, a SSV transformation-specific glycoprotein (SSV ... Full text Link to item Cite

Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses.

Journal Article J Immunol · June 1980 Low m.w. extracts from three known oncogenic viruses, Friend, Moloney, and Rauscher, inhibited the accumulation of macrophages at sites of delayed inflammatory reactions in mice. The potential biologic significance of these proteins is suggested by their p ... Link to item Cite

Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus.

Journal Article Proc Natl Acad Sci U S A · March 1980 There is controversy in the literature concerning the presence in humans of antibodies directed against the envelope glycoproteins of known oncoviruses. In the present report, we show that antibodies capable of precipitating a wide variety of oncoviral gly ... Full text Link to item Cite

Morphological and biochemical properties of a new human breast cancer cell line.

Journal Article Cancer Res · July 1979 DU4475 is a new human breast cell line derived from a cutaneous metastatic nodule from a patient with advanced breast cancer. It has been in continuous culture for more than 1 year and has survived 140 subcultivations. The cells grow in suspension, display ... Link to item Cite

Assembly of type C oncornaviruses: a model.

Journal Article Science · January 13, 1978 The salient features of this model for oncornavirus assembly are that uncleaved precursor molecules to the internal virus polypeptides possess specific recognition sites both for viral envelope constituents already inserted in the cell membrane and for the ... Full text Link to item Cite

The structural polypeptides of equine infections anemia virus.

Journal Article Intervirology · 1978 The structural polypeptides and glycoproteins of equine infectious anemia virus were identified following electrophoresis in SDS-PAGE. The major non-glycosylated polypeptides had molecular weights of 25,000, 14,000 and 11,000 daltons. Two glycoproteins of ... Full text Link to item Cite

Properties of mouse leukemia viruses. XIV. Prevention of spontaneous AKR leukemia by treatment with group-specific antibody against the major virus gp71 glycoprotein.

Journal Article Virology · November 1977 Treatment of AKR mice early in life with potent goat antibody to the major virus glycoprotein (gp71) of Friend leukemia virus resulted in marked prevention of fatal AKR disease. Even better protection could be achieved when, in addition, the mothers were t ... Full text Link to item Cite

Frog oocytes synthesize and completely process the precursor polypeptide to virion structural proteins after microinjection of avian myeloblastosis virus RNA.

Journal Article Proc Natl Acad Sci U S A · August 1977 After microinjection of Xenopus laevis oocytes with RNA from avian myeloblastosis virus, viral structural proteins p27, p19, p15, and p12 are formed by a sequence of posttranslational cleavages of a high-molecular-weight precursor polypeptide. The 60-70S R ... Full text Link to item Cite

Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on surfaces of virus-producing murine and other mammalian species cell lines.

Journal Article Cancer Res · March 1977 The specificity of a single rabbit antiserum pool raised against the purified major glycoprotein, gp71, of Friend murine leukemia virus was determined for a variety of virus-producing mouse, feline, and gibbon ape cell lines by viable cell membrane immunof ... Link to item Cite

Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on the surfaces of normal murine cells.

Journal Article Cancer Res · March 1977 The expression of the major glycoprotein, gp71, of murine leukemia virus was studied on the surfaces of a variety of normal murine cell lines with a monospecific rabbit antiserum raised against purified Friend murine leukemia virus gp71. Using viable cell ... Link to item Cite

Evidence that a precursor glycoprotein is cleaved to yield the major glycoprotein of avian tumor virus.

Journal Article J Virol · February 1977 A glycoprotein designated pr90, which is recognized by anti-gp85 serum, is present in lysates of pulse-labeled transformed cells. Under chase conditions, a reduction in the level of labeled pr90 is observed concomitant with the appearance of labeled, cell- ... Full text Link to item Cite

Role of carbohydrate in biological functions of Friend murine leukemia virus gp71.

Journal Article J Virol · January 1977 Purified gp71 of Friend murine leukemia virus (FLV) can interfere with virus infection, absorb neutralizing antibody, and in the presence of group-specific anti-gp71 antibody, hemagglutinate sheep erythrocytes. Interference by FLV gp71 with several murine ... Full text Link to item Cite

A model for assembly of type-c oncornaviruses.

Journal Article Med Microbiol Immunol · 1977 Full text Link to item Cite

Interspecies determinants of Friend leukemia virus antigens involved in cytolysis of virus-pfoducing cells.

Journal Article J Virol · January 1977 The cytolytic reactivity of a complex goat anti-feline leukemia virus (FeLV) antiserum for mouse cells (Eveline) releasing large quantities of Friend leukemia virus (FLV) was analyzed by the sensitive [14C]nicotinamide release microcytotoxicity assay. Wher ... Full text Link to item Cite

Detection of the major glycoproteins of Friend leukemia virus (gp71) and the murine mammary tumor virus (gp52) on the surface of mouse cells

Journal Article Cancer Research · December 1, 1976 Specific rabbit antisera to the major glycoproteins of Friend leukemia virus (gp71) and the mouse mammary tumor virus (gp52) were utilized to study the surfaces of C3H, DBA, BALB/c, and C57BL transformed and normal cells by immunoelectron microscopy. Antis ... Cite

Virus-infected avian cell lines established in vitro.

Journal Article Cancer Res · November 1976 Four virus-infected avian cell lines have been established in culture. Two of these lines, infected with BAI strain A virus, liberate only small quantities of virus in the culture fluid. The cells retain the ability to induce myeloblastic leukemia when ino ... Link to item Cite

Detection of the major glycoproteins of Friend leukemia virus (gp71) and the murine mammary tumor virus (gp52) on the surface of mouse cells.

Journal Article Cancer Res · September 1976 Specific rabbit antisera to the major glycoproteins of Friend leukemia virus (gp71) and the mouse mammary tumor virus (gp52) were utilized to study the surfaces of C3H-, DBA-, BALB/c-, and C57BL-transformed and normal cells by immunoelectron microscopy. An ... Link to item Cite

Viral glycoprotein synthesis studies in an established line of Japanese quail embryo cells infected with the Bryan high-titer strain of Rous sarcoma virus.

Journal Article J Virol · May 1976 Although a glycoprotein with an approximate molecular weight of 43,000 is associated with purified virions of the Bryan high-titer strain of Rous sarcoma virus propagated on R(-)Q cells, these virions lack gp85, the major glycoprotein of the avian tumor vi ... Full text Link to item Cite

Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice.

Journal Article J Virol · March 1976 The major envelope glycoprotein (gp71) from AKR murine leukemia virus (MuLV) was purified and its serological reactivity with heterologous and autogenous immune mouse sera was examined. Homologous and interspecies competition radioimmunoassays using antise ... Full text Link to item Cite

Relationships between membrane antigens of human leukemic cells and oncogenic RNA virus structural components.

Journal Article J Exp Med · January 1, 1976 Leukemic cells from all human chronic granulocytic leukemia (CGL) and some acute myelomonocytic leukemia (AMML) donors are lysed by rabbit antisera to a purified glycoprotein of Friend murine leukemia virus (FLV gp71) in a microcytotoxicity assay. These an ... Full text Link to item Cite

Virus-infected Avian Cell Lines Established in Vitro

Journal Article Cancer Research · January 1, 1976 Four virus-invected avian cell lines have been established in culture. Two of these lines, infected with BAI strain A virus, liberate only small quantities of virus in the culture fluid. The cells retain the ability to induce myeloblastic leukemia when ino ... Cite

Structural components of RNA tumor viruses

Journal Article OREGON STATE UNIV.PRESS · January 1, 1976 Cite

The antigenic expression of murine leukemia virus GP71 on murine and heterologous species cells

Journal Article Federation Proceedings · January 1, 1976 RNA C type viruses are oncogenic agents in many animal species and in particular are associated with all types of murine leukemia. The expression of the major glycoprotein, gp71, of murine leukemia virus, in which virus neutralizing and type specific deter ... Cite

A novel murine oncornavirus with dual eco- and xenotropic properties.

Journal Article Proc Natl Acad Sci U S A · December 1975 Infection of Swiss mouse 3T3FL cells with a clonal isolate of Moloney leukemia virus (MLV-IC) resulted in virus progeny composed of at least three different murine helper oncornaviruses. Each entity was purified in appropriate cells by several sequential t ... Full text Link to item Cite

Role of carbohydrate in determining the immunochemical properties of the major glycoprotein (gp71) of Friend murine leukemia virus.

Journal Article J Virol · December 1975 Treatment of Friend leukemia virus gp71 with protease-free glycosidase enzymes results in removal of the major portion of the carbohydrate without affecting the amount of protein present. The digested material migrates as protein of about 60,000 to 65,000 ... Full text Link to item Cite

Two levels of restriction by mouse or cat cells of murine sarcoma virus coated by endogenous xenotropic oncornavirus.

Journal Article J Gen Virol · October 1975 Mouse and cat cells were each examined for the mode of restriction of endogenous xenotropic oncornavirus. Murine xenotropic helper virus (MuX) and its pseudo-type of Moloney murine sarcoma virus (MSV(MuX)) were grown in cat cells to high titre. MuX alone d ... Full text Link to item Cite

Mitosis is required for production of murine leukemia virus and structural proteins during de novo infection.

Journal Article J Virol · August 1975 Cloned 3T3FL cells were synchronized in G1 phase of the cell cycle by deprivation of multiplication stimulatory activity of serum and were then infected with Moloney leukemia virus. Eclipse period of virus could be made to vary from less than 10 to 34 h. A ... Full text Link to item Cite

Expression of the Major Viral Glycoprotein of Avian Tumor Virus in Cells of chf(+) Chicken Embryos.

Journal Article J Virol · May 1975 The expression of gp85, the major viral glycoprotein of avian tumor virus, by certain chicken embryonic cells was studied by the use of sera directed to antigenic determinants of subgroup E viral gp85. As analyzed by sodium dodecyl sulfate-polyacrylamide g ... Full text Link to item Cite

Isolation of two subgroup-specific leukemogenic viruses from standard avian myeloblastosis virus.

Journal Article J Virol · April 1975 Two populations of virus having subgroup-specific homogeneity (A and B) were isolated from standard avian myeloblastosis virus stocks by passage in vivo through genetically defined chickens. Each possesses leukemogenic activity in vivo. Other properties an ... Full text Link to item Cite

Polypeptides of mammalian oncornaviruses. II. Characterization of a murine leukemia virus polypeptide (p15) bearing interspecies reactivity.

Journal Article Virology · January 1975 Polypeptide p15 from Friend leukemia virus was isolated by multiple gel filtration steps in guanidine hydrochloride. Because of its marked tendency to aggregate, renaturation of the protein was performed in the presence of 0.2% sodium deoxycholate. Serolog ... Link to item Cite

Reactivity of avian RNA tumor viruses with lectins.

Journal Article J Virol · January 1975 The infectivity of avian RNA tumor viruses was inactivated to varying degrees by treatment with either concanavalin A (Con A) or phytohemagglutinin but not by treatment with wheat germ agglutinin. In general, leukosis viruses reacted preferentially with Co ... Full text Link to item Cite

Morphological, chemical, and antigenic organization of mammalian C-type viruses.

Journal Article Bibl Haematol · 1975 New features in the architecture of mammalian type C viruses, in particular knoblike surface projections and hexagonally arranged subunits on the core shell could be demonstrated by electron microscopy, taking advantage of newly developed preparation techn ... Full text Link to item Cite

Biochemical properties of oncornavirus polypeptides.

Journal Article Biochim Biophys Acta · December 31, 1974 Full text Link to item Cite

Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas.

Journal Article Proc Natl Acad Sci U S A · December 1974 Cultured cells of different chemically-induced C57BL/6N murine sarcomas produced variable amounts of infectious murine leukemia virus (MuLV) and contained proportional amounts of MuLV structural components as determined by radioimmunoassay. Monospecific an ... Full text Link to item Cite

Isolation of the major viral glycoprotein and a putative precursor from cells transformed by avian sarcoma viruses.

Journal Article Proc Natl Acad Sci U S A · June 1974 Immune precipitation with a monospecific antiserum was employed to study the synthesis of the major viral glycoprotein gp85. Labeled gp85 was detectable by polyacrylamide gel electrophoresis of immune precipitates prepared from lysates of transformed cells ... Full text Link to item Cite

Outer membrane of avian myeloblastosis virus.

Journal Article J Virol · December 1973 Guinea pigs immunized intracerebrally with avian myeloblastosis virus (AMV) produced antiserum which reacted with intact virus particles in complement fixation. The antigen in question appeared to be located on the surface of the virion and could be distin ... Full text Link to item Cite

[Chicken RNA tumor viruses: a model for virus-induced carcinogenesis].

Journal Article Zentralbl Bakteriol Orig A · May 1972 Link to item Cite

In vitro chick embryo cell response to strain MC29 avian leukosis virus.

Journal Article J Virol · June 1968 Strain MC29 avian leukosis (myelocytomatosis) virus induced infection, elaboration of virus, and morphological alteration in chick embryo cells in vitro. Virus liberation began within 18 hr, morphological change was detectable at about 40 hr, and the cultu ... Full text Link to item Cite

Inhibitory proteins in the Newcastle disease virus-induced suppression of cell protein synthesis.

Journal Article J Bacteriol · May 1966 Bolognesi, D. P. (Rensselaer Polytechnic Institute, Troy, N.Y.), and D. E. Wilson. Inhibitory proteins in the Newcastle disease virus-induced suppression of cell protein synthesis. J. Bacteriol. 91:1896-1901. 1966.-Infection by Newcastle disease virus brin ... Full text Link to item Cite